Lowest Price Guaranteed
Slides
263
Last Updated
July 2026
View Count
14523
The global bioanalytical testing services market, valued at USD 4.94 billion in 2025, is projected to reach USD 5.38 billion in 2026 and USD 10.90 billion by 2035, representing a CAGR of 8.2% during the forecast period.
To learn more about this report, request a free sample copy
Bioanalytical testing is a process of analyzing biological samples to assess drug efficacy and safety. This information is essential for researchers to determine how drugs react on the body and its efficacy in treating diseases. Moreover, bioanalytical testing also helps with regulatory compliance and faster approval.
With growing preferences for advanced personalized drug formulations, there has been a surge in the demand for bioanalytical testing solutions, such as biomarkers analysis, pharmacokinetics and bioequivalence studies. However, with increasing research on advanced drug formulations, it can be challenging to continue drug research and perform bioanalytical testing simultaneously. Furthermore, setting in-house bioanalytical testing laboratories can be expensive and require skilled personnel for operations. Considering the ongoing challenges, various pharmaceutical companies are shifting to bioanalytical testing services from third-parties. Access to outsourcing services provides technical expertise, reduces cost of installing high-throughput technologies and ensures highly specialized equipment for accurate analysis of biological samples.
In addition, hiring third part services provider for bioanalytical testing saves plenty of time and adheres to regulatory compliance for faster drug approval. Driven by the ongoing trend of outsourcing, various market players are emphasizing expanding bioanalytical testing services and integrated advanced data analysis technologies for precise understanding of biological samples. For instance, in August 2024, SGS launched a new bioanalytical testing services in Hudson, New Hampshire. This newly launched bioanalytical testing service is anticipated to support drug development and discovery specifically during pre-clinical and clinical trials.
Overall, the bioanalytical testing services market is expected to remain competitive and is expected to grow at a substantial rate during the forecast period.
The market research report presents an in-depth analysis of companies that are involved in the global bioanalytical testing services industry, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | USD 5.38 Billion | |
| Market Size 2035 | USD 10.90 Billion | |
| CAGR (Till 2035) | 8.2% | |
| Type of Molecule |
|
|
| Type of Product |
|
|
| Type of Test |
|
|
| Type of Workflow |
|
|
| Type of Technology |
|
|
| Application Area |
|
|
| End Users |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) | Available | |
One of the key objectives of the bioanalytical testing services market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such type of molecule (small molecules, large molecules and others), type of product (reagents, kits, instruments, software and consumables, and other products), type of test (ADME (in-vivo and in-vitro), pharmacokinetics test, pharmacodynamics test, bioavailability, bioequivalence and others), type of workflow (sample preparation (protein precipitation, liquid-liquid extraction and solid phase extraction), sample analysis (hyphenated technique, chromatographic technique, electrophoresis, ligand binding assay, mass spectrometry, nuclear magnetic resonance) and other workflow processes), type of technology (mass spectrometry, chromatography, immunoassay and polymerase chain reaction), application area (oncology, neurology, infectious diseases, gastroenterology, cardiology and other applications), end users (pharma & biopharma companies, contract drug manufacturing organizations, contract research organizations and other end users), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three bioanalytical testing services market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of molecule, the global market is segmented into small molecules, large molecules and others. According to our projections, small molecules segment currently holds 56% of the bioanalytical testing services market share. This is primarily due to the growing demand for tailored drugs designed by using small molecules to target unmet medical needs of the patients. Additionally, small molecules also play a significant role in understanding disease mechanisms and biomedical research, which further underscore the requirement of bioanalytical testing services for analytical study of small molecules.
However, in the long run, large molecule bioanalytical testing service market is expected to grow at a higher CAGR during the forecast period. This can be attributed to the fact that large molecules, such as gene therapy and bispecific antibodies, are highly complex in nature. Thus, pharmaceutical companies required specialized bioanalytical tests for large molecules to ensure efficacy and safety of therapeutic drugs designed by using large molecules.
This segment highlights the distribution of global market across different types of products, such as reagents, kits, instruments, software and consumables, and other products. According to our bioanalytical testing services market forecast, presently reagents account for the highest share of the market. This can be attributed to the fact that reagents play a crucial role in live-cell analysis and extraction of targeted molecules from cellular matrix.
However, in the long run, instruments, and software and consumables segments are expected to grow at a higher CAGR during the forecast period. This is primarily due to the growing demand for advanced software and automated instruments for the analysis of data generated during drug research and clinical studies.
The global market is segmented across different types of tests, such as ADME toxicology testing (in-vivo and in-vitro), pharmacokinetics test, pharmacodynamics test, bioavailability, bioequivalence and others. According to our projection, currently pharmacokinetics test occupies the highest bioanalytical testing services market share (over 45%). This is primarily due to the fact that pharmacokinetics studies help to determine the essential parameters, such as half-life of drug molecules, bioavailability, identify drug-to-drug interactions and drug concentrations. Pharmaceutical companies are presently shifting to contract research organizations for pharmacokinetics tests, which contributed to the highest share of this segment.
However, it is worth noting that bioavailability segment is likely to grow at a higher CAGR during the forecast period. This is potentially due to the rising demand for bioanalytical testing services for generic and super generics drug development. Bioanalytical testing services play a significant role in studying the bioavailability of the drugs after the administration of drugs. Moreover, it also helps in establishing equivalence between early-stage clinical trial formulations and late clinical trial formulations.
This segment is distributed across different types of workflow, such as sample preparation (protein precipitation, liquid-liquid extraction and solid phase extraction), sample analysis (hyphenated technique, chromatographic technique, electrophoresis, ligand binding assay, mass spectrometry, nuclear magnetic resonance) and other workflow processes.
According to our projection, currently the sample analysis segment accounts for the highest share (over 45%) of the bioanalytical testing services industry. This dominance is due to the fact that sample analysis is extremely crucial for the development of drug specifically during clinical stages and commercialization stages. Bioanalytical testing techniques helps in identification of impurities and stability of drug molecules in the sample. Therefore, growing demand for bioanalytical testing techniques for sample analysis is likely to be the key reason for highest share of this segment.
However, in the long run, sample preparation segment is likely to grow at a higher CAGR during the forecast period. This can be attributed to the fact that sample preparation is an important step of drug development. It involves extraction procedure that helps to extract required components from the cellular matrix. The need for cutting-edge technologies for sample extraction processes is likely to fuel the growth of this segment during the forecast period.
The global bioanalytical testing services market is further bifurcated across different types of technology, such as mass spectrometry, chromatography, immunoassay and polymerase chain reaction. According to our projection, mass spectrometry market segment holds the highest share of the market. This can be attributed to the fact that mass spectrometry techniques, such as liquid chromatography-mass spectrometry offer high sensitivity that enable the quantitative analysis of low concentration molecules such as small and large.
Moreover, it provides information about toxicokinetic and pharmacokinetic properties, which is essential to design a tailored drug. Driven by ongoing demand, this segment is likely to grow at a higher CAGR during the forecast period.
This segment highlights the distribution of global market across different types of application areas, such as oncology, neurology, infectious diseases, gastroenterology, cardiology and other applications. According to our projection, currently oncology segment accounts for the highest bioanalytical testing services market share (nearly 85%). This can be attributed to the increasing research on oncology to understand disease progression and development of tailored treatment.
However, it is expected that neurology and cardiology segments are likely to grow at a higher CAGR during the forecast period. This is likely to be the result of.
On the basis of end users, the global market is segmented into pharma & biopharma companies, contract drug manufacturing organizations, contract research organizations and other end users. According to bioanalytical testing services market analysis, pharma & biopharma companies sub segment accounts for more than 45% of the market. This can be attributed to the fact that pharma & biopharma companies are the primary users of bioanalytical testing services.
Additionally, the expanding research on advanced drug formulations specifically, small molecules and biologics has necessitated the requirement for bioanalytical testing services to streamline drug research. Owing to the ongoing trend, this segment will continue to grow at a steady CAGR during the forecast period.
As per our global bioanalytical testing services market analysis, North America is dominating the industry with a share of 44% and the trend of dominance is likely to remain unchanged during the forecast period. This can be attributed to the rising demand for advanced drugs that necessitated the requirement for bioanalytical testing solutions. Additionally, the expanding research on diseases along with preclinical and clinical studies has increased the demand for advanced analytical testing solutions in this region.
In Asia-Pacific, the market for bioanalytical testing services is expected to expand at a higher CAGR during the forecast period. This is primarily due to rising spending on healthcare infrastructure, heightened demand for analytical testing solutions in pharmaceutical companies that are established in this region.
The “Bioanalytical Testing Services Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for bioanalytical testing services providers. The market research report lays emphasis on the bioanalytical testing service solutions that are being offered. Key takeaways of the market report are briefly discussed below.
Currently, the market landscape for bioanalytical testing service providers is immensely competitive, featuring the presence of several well-established and new-entrants. Top market players such as SGS, Thermo Fisher Scientific and Almac are presently accelerating their initiatives to offer broad range of bioanalytical services, including cell-based assays, mass spectrometry, and immunoassays for small molecules and biologics.
In order to leverage competitive edge, several industrial players are focusing on strategic initiatives for the expansion of product portfolio and services. For instance, in December 2024, Sartorius Stedium Biotech inaugurated new Center for Bioprocess Innovation in Marlborough, Massachusetts. This latest state-of-the-art facility is sophisticatedly designed to encourage co-development, collaboration and learning on site with external innovation partners who are applying Sartorius advanced technologies in real-life workflows.
As more market players continue to accelerate their efforts to enhance their services, we believe that the bioanalytical testing services market will remain competitive during the forecast period.
Bioanalytical testing services industry is driven by the rising research on the advanced drugs that demands innovative bioanalytical testing solutions that are expensive and required skilled personnel for smooth operation. Moreover, the pharmaceutical industrial players are shifting towards outsourcing of research and clinical trials to save time for drug development. Additionally, outsourcing services providers offer cutting-edge technologies support and skilled personnel which further raises the adoption of outsourcing services by the pharmaceutical industries.
Some of the potential challenges that are hindering market progress include complex regulatory guidelines and shortage of skilled personnels. Further, it is worth mentioning that bioanalytical field involves complex regulatory guidelines for the approval. Navigating these regulatory guidelines can be challenging for the biopharmaceutical companies but will prove to be an opportunity for the bioanalytical testing services providers.
Additionally, the growing requirement for more advanced analytical tools and methodologies for the analysis of complex drug molecules may create a significant barrier for market players to provide new technologies which can be expensive.
With growing focus on personalized medicine, there has been a surge in the demand for high throughput and precise bioanalytical testing that aid in tailoring treatment to meet individual patients requirement. Additionally, the necessitated guidelines associated with the drug approval to ensure safety and compliance has further raised the demand for advanced bioanalytical testing solutions.
Moreover, the increasing technological innovations in this field such as high-throughput screening, next generation sequencing and mass spectrometry to enhance accuracy, efficiency and speed of bioanalytical testing is the key growth factor for the market. Additionally, increasing outsourcing of clinical and pre-clinical test services to specialized organizations is further offering enormous opportunities to industrial players for driving the innovations.
The global market for bioanalytical testing services is estimated to be valued at USD 5.38 billion in 2026 and is expected to reach USD 10.90 billion by 2035, representing a CAGR of 8.2% during the forecast period. This unprecedented growth is primarily due to the increasing demand for advanced analytical tools for drug research and development.
In order to provide advanced bioanalytical testing services on a large scale, several industrial players are forging partnerships and collaboration agreements. For instance, in May 2024, BioAgilytix and BBI Solutions OEM entered into the partnership to simplify and accelerate bioanalytical testing. The partnership aims to integrate BBI’s ability to produce high-quality customized antibody reagents for a variety of bioanalytical testing applications with BioAgilytix’s renowned bioanalytical testing services.
As more market players continue to drive partnerships for services expansion, this market is likely to remain progressive during the forecast period.
Examples of key players engaged in this domain (which have also been captured in this report) include Almac Group, BioAgilytix Labs, Charles River Laboratories International, Eurofins Scientific, ICON, Intertek Group, IQVIA, Labcorp (Toxikon), Medpace, Pace Analytical Services, SGS, Syneos Health, Sartorius and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies focusing on the development of bioanalytical testing services and solutions.
The market report presents an in-depth analysis, highlighting the capabilities of various bioanalytical testing service providers engaged in this domain across different segments. Amongst other elements, the market report includes:
Several recent developments have taken place in the field of bioanalytical testing services. We have outlined some of these recent initiatives below.